NYSE$CNMD
Conmed Corp. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Second quarter 2024 financial results were announced, with revenue impacted by supply chain challenges.
CONMED Corporation reported its second quarter 2024 financial results, noting that the quarter played out largely as expected but the company has not yet fully recovered from supply chain challenges, delaying commercial reacceleration. The full-year revenue guidance was revised to $1.305 billion to $1.315 billion, and adjusted diluted net earnings per share are now expected to be in the range of $3.95 to $4.02.
- Second quarter 2024 results played out largely as expected.
- Supply chain challenges have delayed commercial reacceleration.
- Full-year reported revenue is now expected to be between $1.305 billion and $1.315 billion.
- Full-year adjusted diluted net earnings per share are expected to be between $3.95 and $4.02.
Headline financials
Revenue & EPS history
Conmed · Revenue · Quarterly
$332M
Revenue by segment
Conmed · $277M total across 2 segments · Q2 2022
- General Surgery$157M—56.6%
- Orthopedic Surgery$120M—43.4%
Forward guidance
CONMED expects full-year reported revenue to be between $1.305 billion and $1.315 billion. The Company now expects full-year adjusted diluted net earnings per share in the range of $3.95 to $4.02.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.0%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+3.0%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+16.5%
Q1 2025
Best reaction
-18.5%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +1.9% | -0.8% | |
| Q4 2025 | -4.0% | +0.3% | +18.9% | |
| Q3 2025 | -0.1% | +0.6% | -9.8% | |
| Q1 2025 | +16.5% | +13.8% | +15.6% | |
| Q4 2024 | -9.0% | -12.1% | -15.2% | |
| Q3 2024 | +5.5% | +9.0% | +14.5% | |
| Q2 2024 | -6.0% | -5.6% | +5.3% | |
| Q1 2024 | -13.2% | -5.7% | +3.9% | |
| Q4 2023 | -11.7% | -13.0% | -15.7% | |
| Q3 2023 | -0.3% | +3.1% | +15.0% | |
| Q2 2023 | -1.6% | +0.8% | -10.1% | |
| Q1 2023 | +11.2% | +9.2% | +2.7% | |
| Q4 2022 | +3.3% | +6.4% | +0.4% | |
| Q3 2022 | -3.3% | -1.0% | +3.2% | |
| Q2 2022 | -2.5% | -4.5% | -10.0% | |
| Q1 2022 | -8.5% | -19.2% | -17.3% | |
| Q4 2021 | +4.9% | +11.0% | +19.6% | |
| Q3 2021 | +1.5% | +2.0% | -5.9% | |
| Q2 2021 | +1.3% | -0.2% | -1.4% | |
| Q1 2021 | +4.8% | +7.0% | +1.5% | |
| Q4 2020 | -4.6% | -6.1% | +3.1% | |
| Q3 2020 | +2.8% | -3.9% | +29.6% | |
| Q2 2020 | +5.5% | -0.4% | +4.8% | |
| Q1 2020 | +9.2% | +0.5% | +8.5% | |
| Q4 2019 | -2.6% | -4.7% | -11.9% | |
| Q3 2019 | +10.4% | +12.9% | +13.7% | |
| Q2 2019 | +7.3% | +4.5% | +15.3% | |
| Q1 2019 | +0.7% | -2.6% | +0.8% | |
| Q4 2018 | +6.1% | +4.9% | +12.8% | |
| Q3 2018 | -0.6% | +1.3% | +0.8% | |
| Q2 2018 | +8.6% | +5.5% | +8.7% | |
| Q1 2018 | +7.2% | +5.3% | +10.7% | |
| Q4 2017 | +10.2% | +7.1% | +6.3% | |
| Q3 2017 | +1.9% | -2.7% | +0.7% | |
| Q2 2017 | -1.3% | +1.3% | -4.1% | |
| Q1 2017 | +4.2% | +6.9% | +7.6% | |
| Q4 2016 | -6.9% | -4.0% | -6.8% | |
| Q3 2016 | +5.0% | +3.3% | +18.3% | |
| Q2 2016 | -17.5% | -16.9% | -17.0% | |
| Q1 2016 | -4.1% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | -18.5% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | +10.7% | — | — | |
| Q4 2014 | -1.4% | — | — | |
| Q3 2014 | +4.4% | — | — | |
| Q2 2014 | -9.5% | — | — | |
| Q1 2014 | -2.8% | — | — | |
| Q4 2013 | +4.2% | — | — | |
| Q3 2013 | -2.7% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -2.7% | — | — | |
| Q4 2012 | +4.6% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | -0.4% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q1 2010 | -0.2% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2010 | -1.8% | — | — | |
| Q3 2011 | -1.8% | — | — | |
| Q2 2011 | -2.3% | — | — | |
| Q4 2010 | -2.3% | — | — | |
| Q2 2010 | -2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro